ASCO: Lenvatinib Slows Resistant Thyroid Ca

CHICAGO (MedPage Today) -- The targeted agent lenvatinib extended progression-free survival among patients with treatment-refractory thyroid cancer, researchers said here. via MedPageToday.com - medical news plus CME for physicians Read More Here..